Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Immunocore logo — Science to Transform Lives

Immunocore

Science to Transform Lives

Founded 2008 United Kingdom Abingdon, United Kingdom 607 employees IPO Total: $975.60M Biotechnology, Health Care +1

General Information

Company Name Immunocore
Founded Year 2008
Location United Kingdom Abingdon, United Kingdom
Employees 607
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage IPO
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Immunocore. To contact Immunocore, visit immunocore.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Immunocore compare?

A PDF of Immunocore and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Immunocore soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Immunocore

Immunocore, founded in 2008 and headquartered in the United Kingdom, is a prominent player in the Biotechnology, Health Care, and Pharmaceutical industries. The company's slogan, "Science to Transform Lives," encapsulates its mission to develop groundbreaking T cell receptor (TCR) biological therapies. These therapies are formulated to address critical unmet needs in oncology, infectious diseases, and autoimmune diseases.

Recently, Immunocore secured a significant $300.00M through a Post Ipo Convertible investment on 01 January 2024. This robust financial backing underscores the market's confidence in their innovative capabilities and potential for monumental impact in its sectors. However, details on the investors involved in this round remain undisclosed.

Business keywords: T Cell Receptor, Immunotherapy, Cancer Therapy, Oncology, Metastatic Melanoma, Infectious Diseases, Autoimmune Diseases, Bispecific Immunotherapies, TCR Technology Platform, Antibody Fragment Engineering, Clinical Trials, Drug Discovery, Biological Therapies, Unmet Patient Needs

Services & Products

Development of TCR therapies
Clinical trials management
Research in immunotherapy
Therapeutic pipeline development

Target Customers

Patients with cancer Patients with infectious diseases Patients with autoimmune diseases Healthcare professionals

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Convertible $300.00M -
01 Jan 2024
Private Placement VC $140.00M 3
General Atlantic Rock Springs Capital RTW Investments
General Atlantic, Rock Springs Capital +1
01 Jul 2022
Series C $43.20M -
01 Feb 2021
Series B $130.00M 8
General Atlantic WuXi Healthcare Ventures Bill & Melinda Gates Foundation
General Atlantic, WuXi Healthcare Ventures +6
01 Mar 2020
Series B $40.00M 1
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
01 Sep 2017
Series A $320.00M 3
Eli Lilly RTW Investments Woodford Patient Capital Trust
Eli Lilly, RTW Investments +1
01 Jul 2015
Grant £2.40M -
01 Oct 2013
Grant Undisclosed -
01 Jan 2011
Corporate Spinout Undisclosed 1
MediGene
01 Jan 2008
Spinout Undisclosed 1
The University of Oxford
The University of Oxford
01 Jan 1999

Immunocore Alternatives & Competitors

View All Alternatives
Immunocore vs
Tmunity Therapeutics
Tmunity Therapeutics

Pioneering the future of immunotherapy through innovative T cell engineering to tackle a diverse arr...

Acquired
12 employees
Biotechnology, Health Care
Compare Immunocore vs Tmunity Therapeutics
Immunocore vs
Genmab
Genmab Denmark

Differentiated human antibody therapeutics for the treatment of cancer

IPO
2981 employees
Biotechnology, Pharmaceutical
Compare Immunocore vs Genmab
Immunocore vs
Anocca
Anocca Sweden

Engineered Immunity

Venture round
122 employees
Biotechnology, Health Care
Compare Immunocore vs Anocca
View all alternatives

FAQ About Immunocore

Science to Transform Lives
Immunocore was founded in 2008.
Immunocore is headquartered in Abingdon, United Kingdom.
Immunocore operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on T Cell Receptor, Immunotherapy, Cancer Therapy and Oncology. Its customers include Patients with cancer, Patients with infectious diseases and Patients with autoimmune diseases.
Immunocore has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Immunocore has approximately 607 employees.
Immunocore has completed 10 funding rounds, raising a total of $975.60M. The latest funding stage is IPO.
Immunocore offers: Development of TCR therapies, Clinical trials management, Research in immunotherapy, Therapeutic pipeline development.
Top alternatives and competitors to Immunocore include Tmunity Therapeutics, Genmab, Anocca, Orca Bio, BlueRock Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunocore and Tmunity Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immunocore, https://bouncewatch.com/company/immunocore, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes